A Phase 1 interventional study of 0.3% OPA-15406 Ointment and 1% OPA-15406 Ointment in Atopic Dermatitis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-03.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.
Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 15th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 1, and was the 3rd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 15–70
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 3 mo–14 yrs
By country, each count listing its studies:
difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 20 Years to 40 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2015.
This study's enrollment of 32 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 177 across the 16 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
13 studies in Dermatitis, Atopic by Otsuka Holdings Co., Ltd.: 2 open now, 2 under way, 2 of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 13 studies in Dermatitis, Atopic by Otsuka Holdings Co., Ltd., this one is the 13th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 1, and was the 3rd registered.
Otsuka Holdings Co., Ltd.’s Dermatitis, Atopic studies by the year they started, since 2012.
2 of the studies testing difamilast in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173478Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | 2026-12 |
| NCT07184645Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing difamilast in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 13 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the safety (especially skin findings) and pharmacokinetics by applying 0.3%, 1%, or 3% formulation of 5g OPA-15406 ointment to a 1000 cm2 area as a single-dose and as a multiple-dose twice daily for 2 weeks in Japanese healthy adult male subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3% OPA-15406 ointment assessed until 48 hours postdose.
Drug: 0.3% OPA-15406 Ointment
32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.
Drug: 1% OPA-15406 Ointment
32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.
Drug: 3% OPA-15406 Ointment
32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned placebo ointment assessed until 48 hours postdose.
Drug: Placebo Ointment
In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
Drug: 0.3% OPA-15406 Ointment
In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
Drug: 1% OPA-15406 Ointment
In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
Drug: 3% OPA-15406 Ointment
In the multiple administration period, same subjects were treated with assigned OPA-15406 ointment placebo twice daily for 14 days and assessed until 48 hours post dose.
Drug: Placebo Ointment
32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
Also known as: OPA-15406 Ointment
32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose
Also known as: OPA-15406 Ointment
32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
Also known as: OPA-15406 Ointment
32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.
Cmax of OPA-15406 in a Single Administration Period
We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the Cmax of OPA-15406.
Time frame: Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hr
Cmax of OPA-15406 in the Multiple Administration Period
We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.
Time frame: Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs at Day 14
AUC12h of OPA-15406 in a Single Administration Period
We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the AUC12h x of OPA-15406.
Time frame: Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs
AUC12h of OPA-15406 in the Multiple Administration Period
We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.
Time frame: Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs at Day 14
| Milestone | 0.3% OPA-15406 Ointment | 1% OPA-15406 Ointment | 3% OPA-15406 Ointment | Placebo |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the Cmax of OPA-15406.
| ng/mL | 0.3% OPA-15406 Ointment in a Single Administration Period | 1% OPA-15406 Ointment in a Single Administration Period | 3% OPA-15406 Ointment in a Single Administration Period |
|---|---|---|---|
| Cmax of OPA-15406 in a Single Administration Period | 0.508 ± 0.304 | 0.838 ± 0.531 | 1.61 ± 0.835 |
We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.
| ng/mL | 0.3 % OPA-15406 Ointment in the Multiple Administration Period | 1 % OPA-15406 Ointment in the Multiple Administration Period | 3% OPA-15406 Ointment in the Multiple Administration Period |
|---|---|---|---|
| Cmax of OPA-15406 in the Multiple Administration Period | 0.506 ± 0.348 | 0.795 ± 0.208 | 1.65 ± 0.462 |
We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the AUC12h x of OPA-15406.
| ng・h/mL | 0.3% OPA-15406 Ointment in a Single Administration Period | 1% OPA-15406 Ointment in a Single Administration Period | 3% OPA-15406 Ointment in a Single Administration Period |
|---|---|---|---|
| AUC12h of OPA-15406 in a Single Administration Period | 3.74 ± 2.32 | 6.42 ± 4.86 | 11.2 ± 6.24 |
We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.
| ng・h/mL | 0.3 % OPA-15406 Ointment in the Multiple Administration Period | 1 % OPA-15406 Ointment in the Multiple Administration Period | 3% OPA-15406 Ointment in the Multiple Administration Period |
|---|---|---|---|
| AUC12h of OPA-15406 in the Multiple Administration Period | 4.65 ± 3.07 | 7.84 ± 1.78 | 16.6 ± 4.99 |
Collected over A single administration: From date of informed consent to 48 hours post dose The multiple administration: From date of assigned IMP twice daily to 16 days post dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.3 % OPA-15406 Ointment in a Single Administration Period | — | 0/8 (0%) | 0/8 (0%) |
| 1% OPA-15406 Ointment in a Single Administaration Period | — | 0/8 (0%) | 0/8 (0%) |
| 3% OPA-15406 Ointment in a Single Administaration Period | — | 0/8 (0%) | 0/8 (0%) |
| Placebo in a Single Adminstaration Period | — | 0/8 (0%) | 0/8 (0%) |
| 0.3 % OPA-15406 Ointment in the Multiple Administration Period | — | 0/8 (0%) | 0/8 (0%) |
| 1 % OPA-15406 Ointment in the Multiple Administration Period | — | 0/8 (0%) | 0/8 (0%) |
| 3 % OPA-15406 Ointment in the Multiple Administration Period | — | 0/8 (0%) | 0/8 (0%) |
| Placebo Ointment in the Multiple Administration Period | — | 0/8 (0%) | 0/8 (0%) |
| Age, Categorical(Participants) | 0.3% OPA-15406 Ointment | 1% OPA-15406 Ointment | 3% OPA-15406 Ointment | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 8 | 8 | 8 | 32 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | 0.3% OPA-15406 Ointment | 1% OPA-15406 Ointment | 3% OPA-15406 Ointment | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 31.9 ± 7.2 | 28.3 ± 7.6 | 30.5 ± 6.7 | 29.5 ± 6.3 | 30.0 ± 6.8 |
| Sex: Female, Male(Participants) | 0.3% OPA-15406 Ointment | 1% OPA-15406 Ointment | 3% OPA-15406 Ointment | Placebo | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 8 | 8 | 8 | 8 | 32 |
| Region of Enrollment(participants) | 0.3% OPA-15406 Ointment | 1% OPA-15406 Ointment | 3% OPA-15406 Ointment | Placebo | Total |
|---|---|---|---|---|---|
| Japan | 8 | 8 | 8 | 8 | 32 |
The record gives a start of Jan 2015, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Difamilast
Otsuka Pharmaceutical Co., Ltd. →